CONTACT US   |  (864) 397-5101

SC Launch Inc. Announces Investment in PulManage

Columbia, SC – South Carolina Research Authority’s investment affiliate, SC Launch Inc., has invested $250,000 in PulManage. The Columbia-based company provides testing and remote monitoring for patients with lung disease.

PulManage, Inc., became an SCRA Member Company in 2019 and successfully matured through the SC Launch Program. It received two $25,000 Project Development Fund Grants, a $50,000 Acceleration Grant, and a $50,000 COVID-19 Response Grant. With this investment, it became an SC Launch Inc. Portfolio Company.

The PulManage platform is advancing the care of lung diseases. It can confirm diagnosis and enhance care management by remotely connecting patients with their healthcare providers. The company’s mission is to improve the management of chronic lung diseases such as COPD, cystic fibrosis, asthma, and other chronic lung diseases. The platform includes patient-facing mobile apps with real-time feedback through an online dashboard for researchers and clinicians. “Not only does the app monitor and record lung function, it’s also improving testing and preventing confusion and misdiagnosis,” said SC Launch Inc. Executive Director Matt Bell. “This means better care and getting care sooner for patients with lung conditions.”

“From the beginning, SCRA’s SC Launch Program team has believed in our mission and supported our growth. We would not be where we are today without their support, positioning us to revolutionize how we care for chronic lung disease,” said PulManage CEO and Founder Amanda Clark. “We value our long-standing partnership with SCRA and SC Launch Inc.”

SCRA President and CEO Bob Quinn said, “We work every day to move innovation forward, and when the innovation is life-sustaining and lifesaving, we are more honored to support our state’s innovators. We are proud of PulManage’s growth and promising future to help even more patients.”

PulManage recently received an exclusive invitation from Amazon Web Services Life Sciences to represent their product as part of the healthcare solutions at the Annual Summit with national and international stakeholders in the digital health, AI, and drug discovery sectors. They will also attend the International BIO convention as part of the South Carolina delegation in San Diego to meet with prospective partners and share more about the platform.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.